No previous suggestions found.

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

1
Home
Companies

Novocure

#4724

Rank

$1.57B

Marketcap

JE Jersey

Country

Novocure
Leadership team

Mr. William F. Doyle (Exec. Chairman)

Mr. Asaf Danziger (Pres, CEO & Director)

Ms. Ashley Cordova (Chief Financial Officer)

Products/ Services
Health Care, Medical Device
Number of Employees
1,000 - 20,000
Headquarters
Jersey, Arkansas, United States
Established
2000
Company Registration
SEC CIK number: 0001645113
Revenue
500M - 1B
Traded as
NVCR
Social Media
URL
https://www.novocure.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
History

Novocure was founded on a big idea from Dr. Yoram Palti – professor of electrical engineering and a cancer survivor – to fight cancer with an innovative therapy called Tumor Treating Fields therapy. Novocure is dedicated to unlocking the potential of Tumor Treating Fields and improving the lives of cancer patients.

Mission
Our mission is to extend lives by developing, manufacturing and commercializing innovative cancer treatments that empower patients, their families and their physicians.
Vision
Our vision is to make Tumor Treating Fields therapy the standard of care for all solid tumor types.
Key Team

Mr. Wilhelmus C. M. Groenhuysen (Chief Operating Officer)

Mr. Pritesh Shah (Chief Commercial Officer)

Prof. Yoram Palti M.D., Ph.D. (Founder & CTO)

Ms. Ingrid Goldberg (VP of Investor Relations)

Mr. Uri Weinberg M.D., Ph.D. (Chief Science Officer)

Mr. Barak Ben Arye (Gen. Counsel)

Mr. William Patrick Burke (Chief HR Officer)

Recognition and Awards
CNBC Disruptor 50, Deloitte's Technology Fast 500, FierceBiotech's Fierce 15, Goldman Sachs' 100 Most Innovative Companies
References

https://in.investing.com/equities/novocure-ltd

https://finance.yahoo.com/quote/NVCR/profile?p=NVCR

https://www.crunchbase.com/organization/novocure

https://sec.report/CIK/0001645113

https://companiesmarketcap.com/

https://www.novocure.com

Novocure
Leadership team

Mr. William F. Doyle (Exec. Chairman)

Mr. Asaf Danziger (Pres, CEO & Director)

Ms. Ashley Cordova (Chief Financial Officer)

Products/ Services
Health Care, Medical Device
Number of Employees
1,000 - 20,000
Headquarters
Jersey, Arkansas, United States
Established
2000
Company Registration
SEC CIK number: 0001645113
Revenue
500M - 1B
Traded as
NVCR
Social Media
URL
https://www.novocure.com
About

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

contacts

businessabc@ztudium.com

Follow Us
Produced by
In collaboration with
Logo

Copyright 2024 © Businessabc powered by ztudium

Privacy Policy